Landon L. Chan
5 Papers
13 Citations
Landon L. Chan is an academic researcher. The author has contributed to research in topics: Quality of life & Survival analysis. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
Winnie Yeo,Frankie Kf Mo,Jane Koh,Anthony T.C. Chan,Thomas W. Leung,Pun Hui,Landon L. Chan,Amanda M. Y. Tang,Jam J. Lee,Tony Mok,Paul B.S. Lai,Philip J. Johnson,B. Zee +12 more
TL;DR: In the studied HCC population, patient-reported baseline QoL provides additional prognostic information that supplements traditional clinical factors, and is a new prognostic marker for survival for patients with unresectable HCC.
117
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
Stephen L. Chan,Paul N. M. Cheng,Angela M Liu,Landon L. Chan,Leung Li,Cheuk Man Chu,Charing C N Chong,Yat M Lau,Winnie Yeo,Kelvin K. Ng,Simon C.H. Yu,Tony Mok,Anthony W.H. Chan +12 more
TL;DR: In this paper, a single arm open-label Phase II trial was conducted to assess the potential clinical efficacy of Pegylated recombinant human arginase (PEG-BCT-100) in chemo-naïve post-sorafenib failure HCC patients.
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma
Landon L. Chan,Stephen L. Chan +1 more
TL;DR: This data indicates that combination strategy with immune checkpoint inhibitor and anti-VEGF agent will likely bring a paradigm shift in systemic treatment of advanced HCC, and further research are needed to identify predictive biomarkers for response and best treatment sequence prioritization.
10
Treatment of high-burden hepatocellular carcinoma: an oncologist perspective
Landon L. Chan,Stephen L. Chan +1 more
TL;DR: The definition of “high-burden HCC” will be based on three factors: size, number of tumors and the presence of macrovascular invasion, and the different treatment modalities, namely surgery, intra-arterial therapy, radiotherapy and systemic therapy, and their respective supportive evidences will be discussed.
Systemic treatment of pancreatic neuroendocrine tumors
Landon L. Chan,Stephen L. Chan +1 more
TL;DR: Pancreatic neuroendocrine tumours are a group of heterogeneous tumours that despite being rare, their incidence is rising and systemic therapy is integral for the management of this rare entity.
1